K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 31.85 HKD -2.3%
Market Cap: 8.9B HKD
Have any thoughts about
KeyMed Biosciences Inc?
Write Note

KeyMed Biosciences Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

KeyMed Biosciences Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
K
KeyMed Biosciences Inc
HKEX:2162
Total Receivables
ÂĄ79.6m
CAGR 3-Years
302%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Receivables
ÂĄ3.2B
CAGR 3-Years
77%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Receivables
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Receivables
ÂĄ3.1B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Receivables
ÂĄ25.5B
CAGR 3-Years
34%
CAGR 5-Years
41%
CAGR 10-Years
46%
Imeik Technology Development Co Ltd
SZSE:300896
Total Receivables
ÂĄ230.8m
CAGR 3-Years
72%
CAGR 5-Years
75%
CAGR 10-Years
N/A
No Stocks Found

KeyMed Biosciences Inc
Glance View

Market Cap
8.9B HKD
Industry
Biotechnology

In the bustling city of Chengdu, China, amid the rise of modern medical innovation, KeyMed Biosciences Inc. has emerged as a prominent player in the biotechnology sector. Established by a team of experienced scientists and industry veterans, the company focuses on the discovery and development of novel biologic therapies aimed at addressing critical unmet medical needs, particularly within the oncology and autoimmune disease spaces. With its proprietary technology platforms, KeyMed drives its research and development by leveraging extensive capabilities in monoclonal antibody discovery and engineering. This approach allows the company to create innovative products that potentially offer superior efficacy and safety profiles compared to existing treatments, thus underpinning its mission to contribute significantly to global healthcare advancements. KeyMed Biosciences operates on a business model primarily centered around product development pipelines, strategic partnerships, and licensing agreements. The company's revenue streams are chiefly generated from licensing out its proprietary drug candidates and technologies to major pharmaceutical companies, who seek late-stage and commercialized assets. These collaborations not only provide the financial means necessary to fuel ongoing R&D but also facilitate accelerated development timelines and expand the reach of their therapeutic innovations. Furthermore, as these candidates progress through clinical trials and receive regulatory approvals, KeyMed stands to gain from milestone payments and, eventually, a share of sales revenues. This symbiotic relationship between cutting-edge research and astute financial strategies defines KeyMed's path forward in a competitive industry landscape.

Intrinsic Value
17.51 HKD
Overvaluation 45%
Intrinsic Value
Price
K

See Also

What is KeyMed Biosciences Inc's Total Receivables?
Total Receivables
79.6m CNY

Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Total Receivables amounts to 79.6m CNY.

What is KeyMed Biosciences Inc's Total Receivables growth rate?
Total Receivables CAGR 3Y
302%

Over the last year, the Total Receivables growth was 969%. The average annual Total Receivables growth rates for KeyMed Biosciences Inc have been 302% over the past three years .

Back to Top